Let’s be honest. Most health and nutrition marketers I talk to still treat Amazon as a conversion line item. It sits in the retail media budget. It reports up through e-commerce. It gets measured on ROAS. And it never crosses paths with the brand team running CTV, the social team running awareness, or the CRM team thinking about loyalty.

That model is broken. And on May 11, 2026, Amazon made it official.

At its 2026 Upfront at the Beacon Theatre in New York, Amazon Ads put a single message in front of every agency buyer in the room: this is no longer a retail media platform. It’s a full-funnel commerce media ecosystem that spans streaming TV, live sports, Twitch, podcasts, creator content, Amazon DSP, and Amazon Marketing Cloud. All connected. All measurable. All sitting on the same authenticated identity graph.

If you work in health, beauty, nutrition, or any category where consumer trust matters more than impressions, what Amazon just announced changes how your media plan should look in 2027. Here’s what actually shifted, what the data says, and where I’d put my budget if I were rebuilding the plan from scratch.

What Amazon Actually Announced

The headline from the 2026 Upfront was a new product called Dynamic TV Creative. It’s the first capability inside Amazon’s Prime Video ad stack that automatically personalizes Interactive Video Ads based on a viewer’s shopping behavior and where they sit in the purchase funnel. Same ad asset. Different version. Adjusted at the moment of impression.

The way it works is straightforward. A viewer who has never seen the brand gets a standard awareness-style ad with a “learn more” call-to-action. A viewer whose shopping signals suggest purchase intent gets a different version with pricing, ratings, and an “add to cart” button. The product imagery, headline copy, and on-screen details all shift based on what Amazon’s authenticated graph knows about the viewer. It launched ahead of the Upfront for select U.S. advertisers in CPG, fashion, and electronics, with wider rollout planned for Q3 2026, including live sports.

That’s the new product. But the bigger story is the system around it.

Source: Amazon Internal, Interactive Video Ads Incrementality Study 2025

Those numbers are the part that should make any digital director uncomfortable. They’re not benchmark lifts against a poorly run campaign. They’re lifts measured against standard streaming TV. The implication is clear: if you’re still buying CTV the old way, you’re leaving outcomes on the table that a competitor running the new format is collecting.

The authenticated graph at the center of everything

The product announcement matters. But what makes it work is Amazon’s authenticated graph, which the company says reaches 90% of U.S. households. Not modeled. Not panel-based. Authenticated through Amazon sign-ins, Fire TV registrations, Prime Video streaming, shopping behavior, and entertainment touchpoints.

Why does that matter for a health and nutrition brand? Two reasons.

First, frequency management actually works. In traditional CTV planning, you assume a household, you assume a demo, and you hope the frequency curve looks something like what you bought. With deterministic identity, you know who you reached, how many times, and what they did next. That’s a different kind of media plan.

Second, and this is the part I keep coming back to, the same graph that powers ad delivery also powers measurement inside Amazon Marketing Cloud. The exposure data, the shopping data, the conversion data, the repeat purchase data, the Subscribe & Save data. All in one clean room. For a category that gets evaluated on lifetime value and repeat behavior more than on a single conversion, that’s not a media improvement. That’s a customer engagement infrastructure upgrade.

Why This Matters More for Health and Nutrition Than for Snacks

Here’s where I think most analysis of the 2026 Upfront gets too generic. Amazon’s pitch applies to every category, but the value isn’t equal. For categories driven by impulse and shelf placement, the upper-funnel investment is a nice-to-have. For categories driven by consumer trust, education, and repeat purchase, the upper-funnel investment is the whole game.

And the data backs that up. eMarketer’s April 2026 industry KPI report shows retail media spend growth in health and beauty jumped more than 50% year-over-year, well ahead of every other category. That’s not happening because the category needs more retail ads. It’s happening because the brands inside the category figured out that retail media is where they can finally pair brand-building with measurable purchase outcomes.

What I tell my team is that in our category, three things are non-negotiable: trust, context, and proof. Amazon’s authenticated reach handles context. The measurement stack handles proof. Trust is something the brand has to earn through the content adjacency it chooses and the creative it puts out. The platform doesn’t do that part for you, but it gives you environments where it can actually happen. Trusted podcasts. Premium sports. Curated streaming. None of that existed inside the old retail media bucket.

“In our category, three things are non-negotiable: trust, context, and proof. Retail media used to handle one of them. Amazon’s full-funnel stack now handles all three.”

A Story from a Real Brand: Aveeno Baby

The Second Story: H&R Block and Privacy-Safe Full-Funnel

The Canadian Context (And Why It’s Already Different)

I write about the Canadian market a lot, so let me bring this home. The Amazon Upfront is a U.S. event. The product launches are U.S.-first. But the shift it signals is more advanced in Canada than most marketers realize.

According to eMarketer’s analysis, Canada ranks second in the world, behind only China, in retail media’s share of total digital ad spend. And the reason is Amazon. Amazon.ca’s dominance in Canadian e-commerce gives Amazon Ads a structurally larger share of the Canadian retail media market than it has in most other countries. Retail media spending in Canada will reach C$3.8 billion in 2026, and digital will account for 80.1% of total media ad spend.

What this means in practical terms is that a Canadian marketer who treats Amazon as a sponsored search bucket is mis-allocating against the realities of their own market. The full-funnel argument isn’t a future-state pitch in Canada. It’s already where the budget is moving.

Try It Yourself: The Full-Funnel Lift Calculator

The Three Mistakes I See Most Often

1. Reporting Amazon on ROAS alone

If your Amazon scorecard ends at ROAS, your media plan is going to keep collapsing toward the bottom of the funnel. ROAS rewards harvesting demand. It does not reward creating demand. And in a category where the next purchase, the third purchase, and the Subscribe & Save renewal matter more than the first one, optimizing for ROAS will quietly starve your future growth. The H&R Block case study didn’t get published because of ROAS. It got published because the team measured cost per acquisition, conversion lift, frequency reduction, and AMC audience efficiency. That’s the scorecard.

2. Separating brand and retail budgets

This is the structural problem I see in almost every organization. The brand team owns Prime Video. The retail team owns Sponsored Products. The two budgets are planned separately, measured separately, and rarely talk to each other. Amazon’s pitch is that the funnel is one system. If you keep planning it as two systems, you don’t get the lift the platform is capable of delivering. According to Marketing Dive, the full-funnel campaigns offering launching this year is designed to unify sponsored ads, display, and streaming TV in a single agentic AI tool. That tells you where Amazon thinks the work should sit.

3. Scaling media before PDPs are ready

This one is the unsexy truth that nobody wants to put on a slide. Amazon media will not save a weak product detail page. If your images are mediocre, your copy is unclear, your reviews are thin, your claims are not properly substantiated, or your comparison story is confusing, scaling Prime Video spend on top of that will just deliver more shoppers to a page that doesn’t convert. I’ve seen this firsthand more times than I want to count. Fix the PDPs. Then scale the media.

What to Do Monday Morning

The Bottom Line

Amazon’s 2026 Upfront wasn’t really about a single product launch. Dynamic TV Creative is interesting. The 6x and 5x lift numbers are interesting. But the actual signal is structural. Amazon is telling the market it has assembled the full stack: deterministic identity, premium video inventory, sports, audio, creator content, programmatic, retail conversion, and clean-room measurement. All inside one system. And it is openly betting that the brands willing to plan against that system as one connected funnel will out-grow the ones that don’t.

The brands that win this next phase won’t be the ones that spend more on Amazon. They’ll be the ones that stop treating Amazon like a checkout aisle and start treating it like what it is becoming: the most complete commerce media network in North America, with a measurement layer that finally lets you connect a Prime Video impression to a Subscribe & Save renewal eighteen months later.

That’s the part most playbooks haven’t caught up to yet. The brands that close that gap first are the ones I’d bet on.

Let’s be honest about what’s happening here. The patient has changed. Not the biology, not the molecule, not the clinical outcome. The patient’s behaviour. Where they go to learn. What they ask. How long they stay. How they make decisions. And if your content strategy was designed for search engine results pages, you are building for the last channel.

Scrunch AI, a platform that tracks what people actually type into ChatGPT and other AI assistants, analysed millions of real GLP-1 conversations from January 2026. What they found is one of the most useful audience maps I’ve seen in years. Five distinct patient archetypes. Five different jobs to be done. And almost none of them are being served by how pharma brands currently produce content.

I want to walk you through those five archetypes, tell you what each one needs, and give you a clear picture of what a modern digital patient engagement strategy looks like in 2026.

This Isn’t Search Optimization. It’s a Different Medium.

When someone types “Ozempic side effects” into Google, they’re looking for a page. When they type the same question into ChatGPT, they’re starting a conversation. And they come back. That’s the part most marketers miss.

Large language models don’t just answer questions. They build context across a session. A patient who starts by asking “how does Wegovy work” may ask three follow-up questions before they get to “is this covered by my insurance.” They move through awareness, comparison, access, side effects, and adherence support, all inside a single conversation. The funnel isn’t linear. It’s iterative.

In my experience, the brands that win in a channel like this aren’t the ones with the biggest media budget. They’re the ones whose content is structured in a way that AI can actually cite, quote, and recommend. That’s a different problem than SEO. And it requires a different kind of content investment.

Here’s what the Scrunch research tells us about who those patients actually are.

The Five Archetypes. What Each One Actually Needs.

These aren’t demographic segments. They’re behavioural states. The same patient can move between archetypes as their journey evolves. Someone starts as a Knowledge Seeker, becomes an Active Evaluator after their doctor visit, then shifts to a Side Effect Navigator three weeks into treatment. What they need from your content changes at every stage.

The Canadian Context Makes This Even More Urgent

Here’s something that makes Canadian patients particularly active AI searchers: coverage in this country is a mess. Health Canada has approved GLP-1 medications for both diabetes and weight management, but provincial coverage rules are inconsistent. In Ontario, Ozempic is listed as a Limited Use drug. In Alberta, patients often need to try other treatments first. And as of January 2026, no provincial public drug plan covers Wegovy for weight loss.

That coverage complexity feeds directly into the Access Seeker archetype. Canadian patients aren’t just asking “does this work.” They’re asking “can I actually get it, and how much will it cost me.” Telus Health data shows weight-management drug spending has more than quadrupled since 2021, and the category grew 61% in 2025 alone. A generic version of Ozempic is expected in late 2026 at roughly 35% of current list price. That’s going to flood the market with new patients. But it doesn’t mean engagement becomes easier. It means the volume of questions gets higher.

What Patients Are Actually Saying (In Their Own Words)

The Scrunch data gives us the archetypes. Reddit gives us the texture. Here’s what real GLP-1 users are saying in communities like r/Ozempic and r/WegovyWeightLoss, the exact language that then shows up in AI conversations.

That last comment is a strategy brief, not a complaint. If a patient has to go to a general AI assistant to understand how to navigate your product’s access process, you have a content gap that someone will eventually fill.

What a Digital Marketer Should Actually Do With This

For Knowledge Seekers: Be the Source, Not the Result

These patients are building their first mental model of this category. They don’t need a product page. They need a clear, medically accurate explanation of how GLP-1 receptor agonists work, what to expect in the first few weeks, and what questions to ask their doctor. Content that’s structured for AI citation, with clean headers, concise factual statements, and linked sources, gets referenced in AI answers. Generic brand copy doesn’t.

For Active Evaluators: Own the Comparison

These patients will switch based on a single piece of content. They’re comparing efficacy, side effect profiles, cost, and format. If you don’t have a page that addresses those comparisons fairly and clearly, the AI will synthesise one from whatever it can find. And that might include your competitor’s positioning. Active Evaluators also respond to real patient outcomes, the kind that Reddit communities generate organically. You should be connecting to that conversation.

For Access Seekers: Solve the Access Problem in Detail

In Canada, this means province-by-province coverage guidance. It means walking someone through a private insurance appeal. It means explaining the difference between Limited Use criteria in Ontario versus special authorization in Alberta. This kind of content doesn’t get built because it’s not glamorous. But it’s the content that ends up cited in ChatGPT conversations.

For Side Effect Navigators: Retention Is a Content Strategy

Between 20% and 50% of patients stop GLP-1 therapy in the first year. A huge chunk of that discontinuation is driven by side effects that feel scary but are manageable. Side Effect Navigators want reassurance and practical guidance, not clinical disclaimers. Consider tools: an interactive side effect tracker, a symptom checker, a week-by-week guide to what’s normal. These aren’t nice-to-haves. They’re retention strategy.

For Regimen Planners: Build Something Worth Returning To

This archetype has above-median income and a high return rate. They treat AI as a coach. The content opportunity here is a tool, not an article. A meal planning guide that accounts for GLP-1-related appetite changes. An exercise protocol designed for patients on injectable therapies. A CRM journey that mirrors the iterative behaviour Scrunch documented. What I tell my team is: if a Regimen Planner finds your content once and it doesn’t give them a reason to come back, you’ve lost your highest-value patient.

The Real Problem Isn’t Content. It’s Infrastructure.

Here’s the uncomfortable truth for most pharma marketers. The five archetypes above each need different content, different formats, different channel strategies, and different measurement frameworks. But most pharmaceutical marketing organisations are built around campaigns, not customer journeys.

And the AI platforms are changing fast. OpenAI launched ChatGPT Health in January 2026. Anthropic followed with Claude for Healthcare four days later. Both now allow patients to connect their actual health records to AI conversations. The questions AI helps them ask will be far more specific than anything a search engine ever handled.

The brands that win will have built the content infrastructure before that shift fully hits. I’ve seen this firsthand in adjacent categories. The brands that invested in patient education content three years early are the ones that show up authoritatively in AI search today. It’s not luck. Search-optimised content from 2022 is now AI-citation-ready content in 2026. The same principle holds going forward.

The Patient Hasn’t Changed. Their Expectations Have.

GLP-1 patients aren’t more demanding than any other patient population. But they’re operating in a category that moves fast, costs a lot, has real side effects, and has inconsistent access. And they’ve discovered that AI gives them faster, more thorough, more personalised answers than most branded healthcare websites.

That’s not a threat to your brand. It’s an invitation. Build content worth citing. Build tools worth returning to. Build journeys that match the iterative, non-linear way patients actually move through this category.

Four million conversations happened in January. The number will be higher in every month after. The question is how many of those conversations will reference your content, your guidance, your voice. Right now, most of them don’t. That’s the gap worth closing.